We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Kidney Stone Lithotripsy Linked to Diabetes

By HospiMedica staff writers
Posted on 10 May 2006
Shockwave therapy for renal stones increased the risk of diabetes by almost 400% and increased the risk of hypertension significantly compared with medical treatment, according to a new follow-up study. More...


In a chart review of 630 patients with renal and proximal ureteral calculi treated with shockwave lithotripsy at the Mayo Clinic (Rochester, MN, USA) in 1985, questionnaires were sent to 578 patients still alive in 2004. The 288 respondents were matched by age, gender, and year of presentation with a cohort of nephrolithiasis patients managed non-surgically.

Almost two decades later, analysis of the data found that lithotripsy increased the risk of developing diabetes 3.75 times that of patients treated medically. Development of diabetes was related to the number of shocks and total intensity of treatment. In the shock-wave group, 16.8% developed diabetes. The risk of developing hypertension, after excluding patients with pre-existing hypertension, was 1.47 times that of patients treated medically. The development of hypertension correlated strongly with bilateral treatments, but not with the total number of shocks, average intensity, or total intensity.

To our knowledge, this is the longest follow-up of patients treated with shockwave lithotripsy and the only study to demonstrate an association with diabetes, said Amy Kranbeck, M.D., and colleagues in an April 2006 online report by the Journal of Urology.

According to the researchers, diabetes in this group could be a result of damage to pancreatic islet cells, caused by microvascular damage to the pancreatic tissue and small hematomas after lithotriptor treatment. The researchers speculated that the hypertension risk might be related to parenchymal or vascular changes in the kidneys, with the risk exacerbated by bilateral treatments.



Related Links:
Mayo Clinic

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.